Drug intelligence / Profile preview

OVT-201

Development stage: Preclinical
Lead developer: OverT Bio
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Parenteral

Overview

OVT-201 is an off-the-shelf, non-MHC-dependent T-cell engager being developed by OverT Bio for the treatment of solid tumors. The therapeutic utilizes a naturally occurring, broadly cancer-reactive gamma delta (γδ) T-cell receptor (TCR) to recognize a novel, non-MHC-dependent protein antigen on tumor cells. OverT Bio employs genetic programming to optimize the binder configuration of the engager. As of 2026, OVT-201 is in the preclinical discovery stage, with candidate nomination anticipated in the first half of 2027.

Beyond the preview

Go deeper on OVT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVT-201.

Explore the full profile